161869-03-0Relevant articles and documents
HIV PROTEASE INHIBITORS
-
Page/Page column 43, (2013/05/21)
Compounds of Formula I are disclosed: wherein A, R1, R2, R3, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which
Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors
Jones, Kristen L.G.,Holloway, M. Katharine,Su, Hua-Poo,Carroll, Steven S.,Burlein, Christine,Touch, Sinoeun,DiStefano, Daniel J.,Sanchez, Rosa I.,Williams, Theresa M.,Vacca, Joseph P.,Coburn, Craig A.
body text, p. 4065 - 4068 (2010/09/04)
A series of HIV-1 protease inhibitors containing an epsilon substituted lysinol backbone was synthesized. Two novel synthetic routes using N-boc-l-glutamic acid alpha-benzyl ester and 2,6-diaminopimelic acid were developed. Incorporation of this epsilon s
Lysine based compounds
-
Page/Page column 20, (2010/02/15)
The present invention provides lysine based compounds of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.